Breaking Down Gilead Sciences’ Rough Quarter

In this segment from the Motley Fool Money radio show, Chris Hill and Jeff Fischer talk about why Gilead Sciences (NASDAQ:GILD) saw a drop in revenue and profits this quarter, which was particularly disappointing given the high expectations investors had for the company — after all, it was a highflier not so long ago.

Read more.

Related

JOIN THE DISCUSSION